Get the Daily Brief
Latest Biotech News
AI and Machine Learning Collaborations Drive Next-Gen Radioligand Cancer Therapies
Eli Lilly has partnered with Lila Bio, a pioneer in AI-enabled protein design, to co-develop radioligand therapies targeting solid tumors. Using Lila’s AI and machine learning platforms, the...
PacBio Launches High-Throughput Carrier Screening Driving Genetic Testing Access
PacBio has expanded into high-throughput carrier screening with a new suite of PureTarget panels leveraging its highly accurate HiFi long-read sequencing technology. These panels consolidate...
Pfizer’s $4.9B Metsera Acquisition Marks Bold Obesity Drug Push
Pfizer has announced its acquisition of Metsera for an initial $4.9 billion upfront payment, aiming to strengthen its position in the obesity drug market. The deal includes contingent milestone...
AI and Machine Learning Drive New Frontiers in Biotech Research and Development
Recent advances demonstrate significant integration of AI and machine learning into various facets of biotech, from disease diagnostics to drug discovery. Researchers at Johns Hopkins University...
FDA Approvals and Regulatory News Shape Therapeutic Landscapes
The FDA has advanced multiple significant approvals impacting biotech therapeutics and diagnostics. Merck’s Keytruda received clearance for a rapid subcutaneous injection formulation, enabling...
Innovations in Gene Editing and Synthetic Biology Expand Therapeutic Possibilities
Biotech researchers have introduced cutting-edge gene editing advances to refine control over gene expression and enhance therapeutic potential. Korean scientists developed a dual-mode CRISPR...
Breakthrough Clinical Data and Trial Progress in Rare and Oncology Diseases
Several biotech firms reported pivotal progress in therapeutic development targeting rare diseases and cancers. Ionis Pharmaceuticals announced positive top-line results in a phase 3 trial for...
Emerging Diagnostics and Noninvasive Testing Technology Enrich Screening and Monitoring
Advances in diagnostic testing are poised to transform disease detection and patient monitoring. Phase Scientific launched a large-scale clinical study of its urine-based HPV test aimed at...
Big Pharma and Biotech Sector Faces Employment Cuts Amid Market Adjustments
The biotech and pharmaceutical industries are experiencing significant workforce reductions. Six major pharma companies—including Novo Nordisk, Merck, Bayer, Bristol Myers Squibb, Pfizer, and...
Novel Mechanistic Insights in Cellular and Molecular Biology Illuminate Therapeutic Targets
Recent studies have uncovered crucial cellular processes and chemical pathways relevant to disease mechanisms and treatment opportunities. Researchers revealed lipids' role in activating...
Plant Growth and Environmental Adaptation Mechanisms Unveiled
Plant biologists have decoded cellular mechanisms that regulate growth and adaptability to changing environments. At the University of Freiburg, researchers identified a molecular growth switch...
Biotech Industry Leadership Changes and Financial Moves Update the Sector Landscape
September 2025 has seen notable leadership appointments and financing activities within the biotech and med-tech sectors. CatalYm appointed Clinton Musil as CFO and chief business officer as it...
Pfizer Accelerates Obesity Portfolio With $4.9B Metsera Deal
Pfizer has struck a deal to acquire Metsera, a biotech focused on obesity and cardiometabolic therapeutics, for $4.9 billion upfront with additional milestone payments potentially raising the...
Roche Sets Ambitious Obesity Goals With New Pipeline and Strategy
Roche outlined plans to become a 'top three' player in the obesity treatment market by 2030, leveraging multiple pipeline assets including acquired candidates from Carmot Therapeutics and...
FDA Approves Merck’s Injectable Keytruda for Faster Cancer Treatment
The FDA has approved an injectable formulation of Merck’s cancer immunotherapy Keytruda (Qlex), reducing administration time to minutes compared to the conventional infusion which takes around 30...
Ionis Pharmaceuticals Eyes FDA Filing After Rare Neurological Disease Trial Success
Ionis Pharmaceuticals reported positive Phase 3 trial data for its antisense oligonucleotide targeting mobility stabilization in Alexander disease, a rare and often fatal neurological disorder....
OGT Secures FDA Authorization for Companion Diagnostic in Acute Leukemia
British genomics firm OGT received FDA de novo clearance for its CytoCell KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic for Syndax Pharmaceuticals’ Revuforj (revumenib). The assay...
MapLight Therapeutics Files IPO to Challenge Bristol Myers in Neuropsychiatric Drugs
MapLight Therapeutics, developing drugs targeting muscarinic receptors for schizophrenia and Alzheimer's psychosis, filed for an IPO aiming to compete with Bristol Myers Squibb’s recently approved...
Stealth BioTherapeutics Wins FDA Approval for Barth Syndrome Drug After Delay
Stealth BioTherapeutics received accelerated FDA approval for elamipretide, a treatment for Barth syndrome, a rare mitochondrial disease, resolving a protracted regulatory process that had...
Capsida Bio Halts Gene Therapy Trial After Pediatric Patient Death
Capsida Bio has suspended its SYNRGY trial of CAP-002, an AAV-based gene therapy for rare STXBP1 encephalopathy, following the death of the first treated child patient. The affected disease causes...